Supernus Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Supernus Pharmaceuticals, Inc.

Oct-29	Supernus Announces Third Quarter 2026 Financial Results SUPN GlobeNewswire
Oct-28	Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree for 'Ms. Represented' Campaign SUPN GlobeNewswire
Oct-21	Supernus Announces Orphan Drug Exclusivity for ONAPGO (apomorphine HCl) SUPN GlobeNewswire
Oct-19	Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 SUPN GlobeNewswire
Sep-02	Supernus Pharmaceuticals to Participate in September Investor Conferences SUPN GlobeNewswire
Aug-31	Chloe Kim Teams Up with Qelbree, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD SUPN GlobeNewswire
Aug-03	Supernus Announces Second Quarter 2026 Financial Results SUPN -6.60% GlobeNewswire
Jul-22	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 SUPN GlobeNewswire
Jul-14	Supernus Celebrates Five-Year Anniversary of Qelbree FDA Approval, Continuing to Deliver on Real-World Experience in ADHD SUPN GlobeNewswire
May-27	Supernus Pharmaceuticals to Participate in June Investor Conferences SUPN GlobeNewswire
May-06	Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference SUPN GlobeNewswire
May-05	Supernus Announces First Quarter 2026 Financial Results SUPN GlobeNewswire
Apr-22	Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 SUPN GlobeNewswire
Feb-24	Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results SUPN GlobeNewswire
Feb-23	Supernus Pharmaceuticals to Participate in March Investor Conferences SUPN GlobeNewswire
Feb-12	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 SUPN GlobeNewswire
Dec-03	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference SUPN GlobeNewswire
Nov-21	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference SUPN GlobeNewswire
Nov-12	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London SUPN GlobeNewswire
Nov-04	Supernus Announces Third Quarter 2025 Financial Results SUPN GlobeNewswire
Oct-21	Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 SUPN GlobeNewswire
Aug-27	Supernus Pharmaceuticals to Participate in September Investor Conferences SUPN GlobeNewswire
Aug-05	Supernus Announces Second Quarter 2025 Financial Results SUPN GlobeNewswire
Jul-31	Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics SUPN +16.09% GlobeNewswire
Jul-28	Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer SUPN GlobeNewswire
Jul-22	Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 SUPN GlobeNewswire
May-29	Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree Content Series with Supernus Pharmaceuticals SUPN GlobeNewswire
May-28	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference SUPN GlobeNewswire
May-28	Supernus Announces Paragraph IV ANDA Filings for Qelbree SUPN GlobeNewswire
May-20	Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals SUPN GlobeNewswire
May-06	Supernus Announces First Quarter 2025 Financial Results SUPN GlobeNewswire

Supernus Pharmaceuticals, Inc.

Recent Articles by Supernus Pharmaceuticals, Inc.

Upgrade your Finviz experience